Brain inflammation is tested through a combination of imaging scans, spinal fluid analysis, and blood-based biomarkers. There is no single definitive test. Instead, doctors use a layered approach, starting with brain imaging and blood work, then moving to more invasive procedures like a spinal tap depending on what they find. The specific tests ordered depend on your symptoms and what condition is suspected.
Why Brain Inflammation Is Hard to Detect
Unlike inflammation in a joint or a wound, brain inflammation doesn’t produce the classic signs you’d expect. There’s no visible redness, swelling, or localized pain the way there would be with, say, an inflamed tendon. Brain inflammation is typically chronic and low-grade, driven by immune cells in the brain called microglia that become overactivated. This means it often shows up indirectly, through cognitive changes, mood disturbances, fatigue, or neurological symptoms that develop gradually over months or years.
Because the symptoms are so nonspecific, testing usually begins after a doctor notices patterns during a neurological exam: memory complaints confirmed by cognitive testing, unexplained changes in behavior, new-onset seizures, or progressive motor problems. Mild cognitive impairment, where someone has noticeable memory or thinking difficulties but can still function independently, is one of the stages that often triggers deeper investigation.
MRI: The First-Line Imaging Test
An MRI is typically the first test ordered when brain inflammation is suspected. Standard MRI sequences can reveal structural changes, but a specific technique called FLAIR (fluid-attenuated inversion recovery) is particularly useful. FLAIR works by suppressing the normal signal from spinal fluid, which makes inflamed or damaged brain tissue stand out with high contrast against the surrounding healthy tissue. This makes it effective at spotting the white-matter lesions seen in conditions like multiple sclerosis, infections, stroke, and encephalopathy.
Contrast-enhanced MRI, where a dye is injected into your vein before the scan, can reveal areas where the blood-brain barrier has broken down. When the brain is inflamed, this barrier becomes “leaky,” allowing the contrast dye to seep into brain tissue and light up on the scan. The number of lesions visible on MRI, particularly T2-weighted lesions, correlates with inflammatory activity and is used to track disease progression over time.
An MRI takes 30 to 60 minutes, requires you to lie still inside the scanner, and involves no radiation. If your doctor suspects autoimmune encephalitis, the MRI findings are a required part of the diagnostic workup, though a normal-looking MRI does not rule out inflammation entirely.
Spinal Fluid Analysis
A lumbar puncture, commonly called a spinal tap, gives doctors a direct look at the fluid surrounding your brain and spinal cord. This cerebrospinal fluid (CSF) carries immune signals and proteins that reveal what’s happening inside the central nervous system. It’s the most informative single test for confirming brain inflammation.
During the procedure, a needle is inserted between two bones in your lower back to collect a small sample of fluid. Before the procedure, your doctor will review your medical history, check for bleeding or clotting disorders with blood tests, and may order a CT scan or MRI to make sure there’s no dangerous swelling. You’ll need to mention any blood-thinning medications or allergies to numbing agents ahead of time.
What Doctors Look for in Spinal Fluid
The lab analyzes several things in your CSF sample. White blood cell count is a basic but important measure; elevated mononuclear cells point toward an immune response in the brain. The IgG index measures whether immune cells are producing antibodies inside the central nervous system rather than in the rest of the body, which is a hallmark of conditions like multiple sclerosis.
Beyond these standard measures, researchers have identified a growing panel of inflammatory proteins in CSF that help with diagnosis. In multiple sclerosis, for example, a combination of specific immune signaling proteins achieved a diagnostic accuracy of 95% in research settings. Some of these proteins are elevated even before a person meets full diagnostic criteria, making them potentially valuable for catching disease early. CSF analysis can also detect antibodies that target brain tissue, which is critical for diagnosing autoimmune encephalitis. Testing should use a broad range of antibody assays; using too narrow a panel is one of the most common reasons for misdiagnosis.
Blood Tests and Emerging Biomarkers
Blood tests are less invasive than a spinal tap and increasingly useful. Two proteins in particular have become leading candidates for tracking brain inflammation and damage through a simple blood draw.
Neurofilament light chain (NfL) is a structural protein found inside nerve fibers. When neurons are damaged, NfL leaks into the bloodstream. Elevated blood NfL levels are associated with disease relapses, worsening disability, brain lesions visible on MRI, and shrinkage of brain and spinal cord tissue. It’s especially useful as an early marker: rising NfL can signal active nerve damage before symptoms fully develop.
GFAP (glial fibrillary acidic protein) comes from a different cell type altogether. It’s released by astrocytes, the support cells in the brain that become activated during inflammation. While NfL reflects nerve fiber damage, GFAP reflects the inflammatory response itself, making it a more direct measure of ongoing brain inflammation. GFAP is increasingly used in clinical research to track disease progression and severity, and it’s currently being measured in at least six clinical trials as a biomarker outcome.
Standard inflammatory markers in blood, like general cytokine panels, can also provide supporting evidence. Proteins involved in immune signaling are often elevated in people with neuroinflammatory conditions, though these are less specific to the brain than NfL or GFAP. In 2024, the FDA approved the first blood test for Alzheimer’s disease diagnosis, measuring specific proteins linked to the disease’s hallmark brain changes, signaling a shift toward blood-based neurological testing becoming part of routine clinical care.
PET Scans for Microglial Activity
For a more detailed and direct picture of brain inflammation, PET scans can visualize the activity of microglia, the brain’s resident immune cells. These scans use a radioactive tracer that binds to a protein called TSPO, which is produced in much higher quantities when microglia are activated. In healthy brain tissue, TSPO levels are low, creating a clear contrast when inflammation is present.
TSPO PET imaging has been validated across a wide range of neurological conditions, including Alzheimer’s disease, Huntington’s disease, stroke, brain injury, and epilepsy. The signal reliably overlaps with areas of known brain pathology and with regions where inflammation has been confirmed through tissue analysis. One of its most promising features is that the PET signal decreases when anti-inflammatory treatments are working, making it a potential tool for monitoring whether a therapy is effective.
PET scans are not routine. They’re expensive, require specialized facilities, and expose you to a small amount of radiation. They’re primarily used in research settings and in complex cases where other tests haven’t provided a clear answer.
How These Tests Work Together
Diagnosing brain inflammation is rarely about a single test result. For autoimmune encephalitis, published diagnostic criteria require clinicians to evaluate MRI findings, CSF results, and antibody testing together, while systematically ruling out other possible causes like infections or tumors. Misdiagnosis most commonly happens when doctors skip one of these steps: not fully evaluating MRI and CSF changes, not testing for a broad enough range of antibodies, or not ruling out alternative diagnoses thoroughly.
A typical diagnostic path starts with an MRI and basic blood work. If those suggest inflammation or if clinical suspicion remains high, a lumbar puncture follows. Blood-based biomarkers like NfL and GFAP may be ordered alongside or as a monitoring tool over time. PET imaging is reserved for cases that remain unclear or for tracking treatment response in specific conditions. The combination you receive depends on what condition your doctor suspects, how quickly symptoms are progressing, and what each successive test reveals.